- About Us
- Cancer Survivors
Dr. Marie Plante, Chief of the Gynecologic Oncology Division, Laval University; Chief of the Gynecology Service, l’Hôotel-Dieu de Québec; President of the Society of Gynecologic Oncologists of Canada.
Dr. Plante received her medical degree from Laval University in 1985 and completed her residency in Obstetrics and Gynecology at McGill University in 1990. She then completed a 3-year fellowship training in Gynecologic Oncology at Memorial Sloan-Kettering Cancer Center in New-York in 1993. Since then she has been on staff at l’Hotel-Dieu de Québec. Dr. Marie Plante is currently Associate Full Professor in the Department of Obstetrics and Gynecology at Laval University. She is Chief of the Gynecologic Oncology Division at Laval University and Chief of the Gynecology Service at l’Hôotel-Dieu de Québec. She is also in charge of the clinical research in gynecologic oncology at l’Hôotel-Dieu de Québec and Program Director of the fellowship program in gyn oncology.
Dr. Plante iwas currently President of Society of Gynecologic Oncologists of Canada (GOC) (2008–2010) and council member of the Nominating Committee at the International Gynecologic Cancer Society (IGCS). She has been involved with the American Fertile Hope Organization as well. Dr Plante has major interest in minimally invasive surgical (MIS) approaches in the treatment of gynecologic cancers and specifically in fertility-preserving surgery for young women with cervical cancer. She has extensively published on the radical trachelectomy procedure, a procedure which allows uterine preservation and fertility preservation in young women with early-stage cervical cancer. She has written numerous book chapters and presented at numerous national and international meetings. She has been involved in several hands-on courses and has taught the procedure to numerous fellows in training and gynecologic oncologists from Canada and abroad.
Dr Plante is currently the Principal Investigator (PI) of a large prospective international and randomized trial lead by the NCI-Canada and the Gynecologic Cancer InterGroup (GCIG) comparing less radical surgery in women with small volume disease (< 2 cm) (CX-5/SHAPE trial)